Myelodyplastic Syndrome (MDS) & Chronic myelomonocytic leukemia (CMML)

**HIGHER RISK MDS**
- Naive to Hypomethylating Agents with TP53 mutation
  - HEMMDS0037
    - Phase III
    - APR-246 + Azacitidine vs Azacitidine Alone in TP53 Mutant Myelodysplastic Syndromes
    - PI: Greenberg
    - Aprea Therapeutics

**LOWER RISK MDS**
- Failed to respond to Hypomethylating agent
  - HEMMDS0035
    - (Non-therapeutic trial)
    - Biologically Focused Therapy of Treatment-Refractory MDS Patients
    - PI: Greenberg
    - Stanford
  - Failure to respond to Erythropoietic stimulating Agent
    - HEMMDS0034
      - Phase I Splicing Modulator H3B-8800 in MDS, AML, and CML
      - PI: Greenberg
      - H3 Biomedicine Inc

**KEY**
- Pending
- Open for Enrollment
- Link
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold

*Please mark up a copy using black ink and email changes to SRC-office@stanford.edu*